Valuation: CStone Pharmaceuticals

Market Cap 8.18B 1.21B 1.05B 983M 897M 1.69B 116B 1.72B 11.53B 4.52B 57.86B 4.55B 4.45B 193B P/E 2026 *
-384x
P/E 2027 * 7.64x
Enterprise Value 7.65B 1.13B 982M 920M 839M 1.58B 108B 1.61B 10.78B 4.23B 54.12B 4.26B 4.16B 181B EV / Sales 2026 *
16x
EV / Sales 2027 * 2.67x
Free-Float
80.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: CStone Pharmaceuticals

1 day-1.41%
1 week-1.41%
Current month-1.41%
1 month-1.41%
3 months-30.69%
6 months-0.41%
Current year-21.61%
1 week 0.7
Extreme 0.7
0.7
1 month 0.7
Extreme 0.7
0.7
Current year 0.59
Extreme 0.5945
1.01
1 year 0.59
Extreme 0.5945
1.01
3 years 0.11
Extreme 0.1139
1.01
5 years 0.11
Extreme 0.1139
1.78
10 years 0
Extreme 0.0001
2.6
Manager TitleAgeSince
Chief Executive Officer 62 25/08/2022
Director of Finance/CFO - 18/01/2023
Chief Operating Officer 46 01/08/2016
Director TitleAgeSince
Chairman 55 -
Director/Board Member 62 25/08/2022
Director/Board Member 63 09/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
-1.41%-1.41% - - 1.09B
-1.37%+4.78%+45.99%-1.23% 80.69B
+2.55%+13.07%+2.40%+30.48% 51.22B
+0.49%+2.17%+22.60%+177.89% 49.58B
+2.87%+11.29%-46.98%-47.72% 45.5B
-1.56%-2.19%+59.29%-25.50% 30.6B
-0.39%+0.39%+52.89%+83.63% 24.64B
+1.27%+6.28%+137.81%-40.32% 23.88B
-1.80%+11.10%+4.71%+196.74% 21.59B
-5.89%+34.09%-0.99%+792.56% 17.09B
Average -0.52%+182.05%+30.86%+129.61% 38.31B
Weighted average by Cap. +0.02%+270.79%+27.00%+76.05%

Financials

2026 *2027 *
Net sales 479M 71.04M 61.56M 57.63M 52.59M 98.96M 6.78B 101M 676M 265M 3.39B 267M 261M 11.31B 1.71B 254M 220M 206M 188M 354M 24.22B 360M 2.42B 946M 12.12B 953M 933M 40.44B
Net income -243M -36.05M -31.24M -29.24M -26.68M -50.21M -3.44B -51.06M -343M -134M -1.72B -135M -132M -5.74B 687M 102M 88.3M 82.66M 75.42M 142M 9.72B 144M 969M 380M 4.86B 383M 374M 16.23B
Net Debt -528M -78.29M -67.84M -63.51M -57.95M -109M -7.47B -111M -745M -292M -3.74B -294M -288M -12.47B -3.6B -534M -463M -433M -395M -744M -50.93B -756M -5.08B -1.99B -25.49B -2.01B -1.96B -85.05B
Logo CStone Pharmaceuticals
CStone Pharmaceuticals is an investment holding company primarily engaged in research and development of therapies for oncology, autoimmune and inflammation, and other key disease areas. Through its subsidiaries, the Company is primarily engaged in the research and development of biopharmaceutical products, the sales of pharmaceutical products, as well as the provision of license of its intellectual property (IP) or commercialization license. The Company’s products primarily include targeted therapies, AYVAKIT (avapritinib), GAVRETO (pralsetinib) and CEJEMLY (sugemalimab). The Company is also engaged in the development and commercialization of immuno-oncology. The Company primarily conducts its businesses in the domestic market and overseas markets, such as Central and Eastern Europe and Switzerland.
Employees
136
Date Price Change Volume
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.116CNY
Average target price
12.33CNY
Spread / Average Target
+141.03%

Quarterly revenue - Rate of surprise